Two people in Japan have died after receiving Moderna covid vaccines from a batch contaminated with what is believed to be metallic particles
The vaccines were suspended as a precaution after some of the vials were found to be contaminated with an unknown foreign substance that ‘reacts to magnets’
According to the Japan Times newspaper, 39 vials or 390 doses were found to have been affected.
BYPASS THE CENSORS
Sign up to get unfiltered news delivered straight to your inbox.
You can unsubscribe any time. By subscribing you agree to our Terms of Use
Around 1.6 million doses of Moderna’s covid vaccine were taken out of use after several vaccination centres reported that the vials contained foreign matter, Japans Ministry of Health, Labor and Welfare said early Thursday.
RT reports: The victims were men in their 30s, each of whom received their second Moderna doses from one of three manufacturing lots that were suspended on Thursday, the Health Ministry said on Saturday. An investigation into the cause of deaths is underway.
Japan’s rollout of more than 1.63 million doses was halted after the vaccine’s domestic distributor, Takeda, alerted the government about the foreign material discovered in 39 unused vials. All contaminated doses were manufactured at a Madrid factory run by a Spanish firm Rovi, which said that the vials in question belonged to a batch exclusively shipped to Japan.
The composition of the foreign substance was not immediately clear. However, Japan’s TV channel NHK reported that some doses were contaminated with metal particles, citing Health Ministry sources.
Vaccines from the possibly contaminated lots had been sent to 863 vaccination sites across Japan.
Taro Kono, the minister in charge of the country’s immunization campaign, said on Friday that more than 500,000 inoculations have been already made using the doses from the lots in question. “It doesn’t appear like there are any serious safety issues at this point,” Kono said.
Nevertheless, Moderna announced an investigation into the matter, and the EU’s drug regulator, the European Medicines Agency (EMA), launched its own probe to determine if the European supply was impacted.
